

# Bernd Kaina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6327669/publications.pdf>

Version: 2024-02-01

77  
papers

6,696  
citations

76196

40  
h-index

76769

74  
g-index

78  
all docs

78  
docs citations

78  
times ranked

9349  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose response to methylating agents in the $\gamma$ H2AX, SCE and colony formation assays: Effect of MGMT and MPG overexpression. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2022, 876-877, 503462.	0.9	0
2	Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. <i>Cancers</i> , 2022, 14, 2233.	1.7	19
3	Curcumin Administered as Micellar Solution Suppresses Intestinal Inflammation and Colorectal Carcinogenesis. <i>Nutrition and Cancer</i> , 2021, 73, 686-693.	0.9	11
4	Do Carcinogens Have a Threshold Dose? The Pros and Cons. , 2021, , 1-19.		0
5	Impaired DNA repair in mouse monocytes compared to macrophages and precursors. <i>DNA Repair</i> , 2021, 98, 103037.	1.3	7
6	Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment. <i>Cancers</i> , 2021, 13, 3585.	1.7	19
7	Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar Curcumin. <i>Nutrients</i> , 2021, 13, 2385.	1.7	14
8	Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1789-1799.	1.9	14
9	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10672.	1.8	5
10	Do Carcinogens Have a Threshold Dose? The Pros and Cons. , 2021, , 555-573.		0
11	Comparison of DNA repair and radiosensitivity of different blood cell populations. <i>Scientific Reports</i> , 2021, 11, 2478.	1.6	67
12	Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 779-792.	1.2	5
13	Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells. <i>Cancers</i> , 2021, 13, 6287.	1.7	8
14	Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7006.	1.8	9
15	A genome-wide screening for DNA repair genes: much more players than hitherto known. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 204.	7.1	3
16	Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence. <i>Nucleic Acids Research</i> , 2020, 48, 12085-12101.	6.5	23
17	Human primary endothelial cells are impaired in nucleotide excision repair and sensitive to benzo[a]pyrene compared with smooth muscle cells and pericytes. <i>Scientific Reports</i> , 2019, 9, 13800.	1.6	12
18	DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. <i>DNA Repair</i> , 2019, 78, 128-141.	1.3	89

#	ARTICLE	IF	CITATIONS
19	Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1562.	1.8	41
20	The SIAH1- $\beta$ -HIPK2-p53-ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death. <i>Molecular Cancer Research</i> , 2019, 17, 1129-1141.	1.5	40
21	Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> 2019, 7, 69. <i>Biomedicines</i> , 2019, 7, 90.	1.4	30
22	Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O6-methylguanine in vivo. <i>Archives of Toxicology</i> , 2019, 93, 559-572.	1.9	17
23	Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF- $\kappa$ B. <i>Cancer Research</i> , 2019, 79, 99-113.	0.4	126
24	Werner syndrome (WRN) DNA helicase and base excision repair (BER) factors maintain endothelial homeostasis. <i>DNA Repair</i> , 2019, 73, 17-27.	1.3	7
25	Compromised DNA Repair and Signalling in Human Granulocytes. <i>Journal of Innate Immunity</i> , 2019, 11, 74-85.	1.8	12
26	Epigenetic regulation of DNA repair genes and implications for tumor therapy. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 780, 15-28.	2.4	59
27	PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4061-E4070.	3.3	66
28	Repair gene O <sup>6</sup> -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation. <i>Journal of Neurochemistry</i> , 2018, 144, 139-151.	2.1	41
29	Sensitivity of CD3/CD28-stimulated versus non-stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in the differential radiation response. <i>Cell Death and Disease</i> , 2018, 9, 1053.	2.7	40
30	Genotoxicity testing: Comparison of the $\gamma$ H2AX focus assay with the alkaline and neutral comet assays. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2017, 822, 10-18.	0.9	29
31	Impact of DNA repair on the dose-response of colorectal cancer formation induced by dietary carcinogens. <i>Food and Chemical Toxicology</i> , 2017, 106, 583-594.	1.8	28
32	Death of Monocytes through Oxidative Burst of Macrophages and Neutrophils: Killing in Trans. <i>PLoS ONE</i> , 2017, 12, e0170347.	1.1	42
33	Integrin $\beta$ 3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. <i>Oncotarget</i> , 2017, 8, 27754-27771.	0.8	28
34	MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. <i>Clinical Epigenetics</i> , 2016, 8, 49.	1.8	59
35	Adaptive upregulation of DNA repair genes following benzo(a)pyrene diol epoxide protects against cell death at the expense of mutations. <i>Nucleic Acids Research</i> , 2016, 44, 10727-10743.	6.5	37
36	DNA damage and the balance between survival and death in cancer biology. <i>Nature Reviews Cancer</i> , 2016, 16, 20-33.	12.8	870

#	ARTICLE	IF	CITATIONS
37	Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. <i>Oncotarget</i> , 2015, 6, 33755-33768.	0.8	42
38	Theoretical considerations for thresholds in chemical carcinogenesis. <i>Mutation Research - Reviews in Mutation Research</i> , 2015, 765, 56-67.	2.4	31
39	DNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis. <i>Carcinogenesis</i> , 2015, 36, 1235-1244.	1.3	42
40	The eucalyptus oil ingredient 1,8-cineol induces oxidative DNA damage. <i>Archives of Toxicology</i> , 2015, 89, 797-805.	1.9	42
41	DNA breaks and chromosomal aberrations arise when replication meets base excision repair. <i>Journal of Cell Biology</i> , 2014, 206, 29-43.	2.3	115
42	The $\gamma$ -H2AX Assay for Genotoxic and Nongenotoxic Agents: Comparison of H2AX Phosphorylation with Cell Death Response. <i>Toxicological Sciences</i> , 2014, 140, 103-117.	1.4	106
43	Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2529-2540.	1.9	85
44	DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. <i>Cancer Letters</i> , 2013, 332, 237-248.	3.2	720
45	O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. <i>Carcinogenesis</i> , 2013, 34, 2435-2442.	1.3	84
46	Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. <i>Nucleic Acids Research</i> , 2013, 41, 8403-8420.	6.5	201
47	Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA Damage. <i>PLoS ONE</i> , 2013, 8, e55665.	1.1	218
48	Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response. <i>PLoS ONE</i> , 2013, 8, e83384.	1.1	80
49	Human Monocytes Undergo Excessive Apoptosis following Temozolomide Activating the ATM/ATR Pathway While Dendritic Cells and Macrophages Are Resistant. <i>PLoS ONE</i> , 2012, 7, e39956.	1.1	53
50	Temozolomide Dosing Regimens for Glioma Patients. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 286-293.	2.0	34
51	Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2224-2233.	1.9	142
52	Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN- $\gamma$ and Valproic Acid. <i>Cancer Research</i> , 2011, 71, 4150-4160.	0.4	31
53	Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21105-21110.	3.3	153
54	Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3663-3681.	2.4	124

#	ARTICLE	IF	CITATIONS
55	MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. <i>International Journal of Cancer</i> , 2010, 127, 2106-2118.	2.3	97
56	Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. <i>Carcinogenesis</i> , 2010, 31, 2111-2117.	1.3	61
57	Processing of O <sup>6</sup> -methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. <i>Cell Cycle</i> , 2010, 9, 168-178.	1.3	128
58	Topotecan Triggers Apoptosis in p53-Deficient Cells by Forcing Degradation of XIAP and Survivin Thereby Activating Caspase-3-Mediated Bid Cleavage. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 316-325.	1.3	33
59	Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage. <i>Nucleic Acids Research</i> , 2010, 38, 6418-6432.	6.5	52
60	MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. <i>International Journal of Cancer</i> , 2008, 122, 1391-1399.	2.3	96
61	Human Monocytes, but not Dendritic Cells Derived from Them, Are Defective in Base Excision Repair and Hypersensitive to Methylating Agents. <i>Cancer Research</i> , 2007, 67, 26-31.	0.4	52
62	MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. <i>DNA Repair</i> , 2007, 6, 1079-1099.	1.3	549
63	Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2007, 82, 85-89.	1.4	39
64	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <i>Journal of Neurochemistry</i> , 2006, 96, 766-776.	2.1	290
65	Topotecan-Triggered Degradation of Topoisomerase I Is p53-Dependent and Impacts Cell Survival. <i>Cancer Research</i> , 2005, 65, 8920-8926.	0.4	44
66	Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. <i>Oncogene</i> , 2004, 23, 359-367.	2.6	114
67	Variability and regulation of O6-alkylguanine-DNA alkyltransferase. <i>Carcinogenesis</i> , 2003, 24, 625-635.	1.3	168
68	Long-time expression of DNA repair enzymes MGMT and APE in human peripheral blood mononuclear cells. <i>Archives of Toxicology</i> , 2001, 75, 306-312.	1.9	33
69	BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. <i>Progress in Molecular Biology and Translational Science</i> , 2001, 68, 41-54.	1.9	82
70	DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts. <i>Carcinogenesis</i> , 2001, 22, 579-585.	1.3	99
71	Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches. <i>Cancer Gene Therapy</i> , 2000, 7, 107-117.	2.2	53
72	Nuclear Translocation of Mismatch Repair Proteins MSH2 and MSH6 as a Response of Cells to Alkylating Agents. <i>Journal of Biological Chemistry</i> , 2000, 275, 36256-36262.	1.6	85

#	ARTICLE	IF	CITATIONS
73	Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex <sup>+</sup> , Mex <sup>-</sup> and methylation-tolerant mismatch repair compromised cells: facts and models. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 381, 227-241.	0.4	169
74	Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis, 1996, 17, 2329-2336.	1.3	113
75	Contribution of O6-alkylguanine and N-alkylpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: New insights gained from studies of genetically engineered mammalian cell lines. Environmental and Molecular Mutagenesis, 1993, 22, 283-292.	0.9	115
76	Dependency of the yield of sister-chromatid exchanges induced by alkylating agents on fixation time. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1985, 149, 451-461.	0.4	32
77	Temozolomide – “Just a Radiosensitizer?”. Frontiers in Oncology, 0, 12, .	1.3	7